All News
Multi-ancestry analysis reveals novel genetic loci associated with Osteoarthritis
The first large multi-ancestry genetics study of osteoarthritis (OA) has found 10 novel OA-associated genetic loci, and results showed some of the OA-associated regions are robustly found in every population ancestry studied.
Read Article
TARGET Trial - Cardiovascular Risk Reduction in Rheumatoid Arthritis
A recent randomised clinical trial suggests immunomodulators reduce arterial inflammation, and thereby cardiovascular (CV) risk, but shows no significant benefit to TNF inhibitors over triple therapy in patients with rheumatoid arthritis (RA).
Read Article
Comparing Biosimilar Growth in the US, Germany, and Switzerland
The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe.
Read Article
Fat and bone are never alone: osteoporotic fracture in RA
Dr. David Liew ( @drdavidliew) discusses Abstract 889 at #ACR22. Abstract 889: Serum Adipokines Predict Incident Osteoporotic Fracture in Patients with Rheumatoid Arthritis
https://t.co/jSFmOiQb6N https://t.co/JTXugoxofP
Links:
Dr. John Cush RheumNow ( View Tweet)
Gender Differences in axSpA
In abstract 1614, Dr. Poddubnyy presents the results of the PROOF study which assessed the probability of achieving inactive disease or low disease activity among males and females who were recently diagnosed with axSpA.
https://t.co/DL2TDgXJnG https://t.co/XSQxWWnQgD
Links:
Dr. John Cush RheumNow ( View Tweet)
Lupus Linked With Greater Risk of Cardiovascular Complications of Childbirth
Pregnant women with SLE were more prone to cardiovascular complications during delivery, and their risk seems to have increased over the past 15 years, according to data.
https://t.co/mRUOVrKbt2 https://t.co/m18DWxSV20
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of US National Inpatient Sample data 2015-2019 looked at 60,360 gout admissions, roughly 1/4 had Arrhythmias (mostly older pts; AFib (88%), atr flutter (6.2%), VTach (3.2%). Gout-arrhythmia pts had more deaths (adj OR 2.06) https://t.co/L1WEsybI7h https://t.co/xwAfFVJOuk
Links:
Dr. John Cush RheumNow ( View Tweet)
In pts undergoing hip or knee arthroplasty for OA, aspirin (3.45%) compared with enoxaparin (1.82%) resulted in a significantly higher rate of symptomatic VTE within 90 days, defined as below- or above-knee DVT or pulmonary embolism https://t.co/7hgLbynNx6 https://t.co/HMc4UbMcdy
Links:
Dr. John Cush RheumNow ( View Tweet)
RA-ILD takes centre stage
Greg McDermott presented abstract 2248 on the prevalence and mortality of subpleural interstitial lung abnormalities (ILA) in RA and non-RA comparators.
https://t.co/zrg7IEhBfg https://t.co/dKACCzr4CZ
Links:
Dr. John Cush RheumNow ( View Tweet)
More Than a Conference:Life’s Lessons
By: @KDAO2011
This is my 20th year attending the ACR meeting; despite my virtual attendance, I was still able to connect w/people. I reflected on my experiences w/ the conference and wanted to share my life lessons.
https… https://t.co/9gBbaYBujc
Dr. John Cush RheumNow ( View Tweet)
MTX side effects more prominent in PsA than RA pts. Study of 240 PsA & 86108 RA pts starting either MTX or TNFi. TNFi AE same betw PsA & RA, but MTX adverse greater in PsA (44.8% vs. 29.4%), especially N/V, abdominal pain, depression, tinnitus https://t.co/0QBc6sb900 https://t.co/FZibAeFDBx
Links:
Dr. John Cush RheumNow ( View Tweet)
Sleep Quality & PsA
Abstract #0387 presented at #ACR22 attempted to shed light in this important quality of life determinant. 247 adult PsA patients were included in this study and their sleep quality was measured using the PSQI questionnaire.
https://t.co/lLTnrh2yxG https://t.co/9ViEnEFE6c
Links:
Dr. John Cush RheumNow ( View Tweet)
Humira biosimilars became available in EU 10/18; and will soon be available in the USA w/ Amjevita (Amgen) available Jan 2023 & 6 others (Pfizer, BI, Samsung, Coherus, Sandoz, Biocon) after July 2023. https://t.co/LH3MpT0o9O https://t.co/VeCbcdq5Ie
Links:
Dr. John Cush RheumNow ( View Tweet)
Methotrexate + pegloticase increases response rates in gout
Patients with refractory gout and those with high burden of tophi have only few options when it comes to uric acid lowering agents.
https://t.co/8cqsAXuzIB https://t.co/OSpf5ehiCm
Links:
Dr. John Cush RheumNow ( View Tweet)
Best of ACR Day Two in PSA
https://t.co/FXGCPaTGX6 https://t.co/WICtjVICC2
Links:
Dr. John Cush RheumNow ( View Tweet)
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash ( @drpnash) discusses Abstract 1018 at #ACR22 Convergence.
https://t.co/Wk3ibuh9ip https://t.co/FcLjDMJCgr
Links:
Dr. John Cush RheumNow ( View Tweet)
Low-grade Proteinuria in Non Renal Lupus: Should We be Worried?
Dr. Yuz Yusof ( @Yuz6Yusof) discusses Abstract 1463 presented at #ACR22
https://t.co/v5fHfwvapv https://t.co/zf2kJy23r2
Links:
Dr. John Cush RheumNow ( View Tweet)
Opioid use in PsA and SpA
Dr. Eric Dein discusses Abstract 1012 at ACR22 Convergence
https://t.co/Doxbk7qW33 https://t.co/2UX07T2JpS
Links:
Dr. John Cush RheumNow ( View Tweet)
CAR-T Therapies in Antiphospholipid Antibody Syndrome
Dr. Putman and Dr. Konig discuss abstract 1677 at ACR22 Convergence. Abstract 1677: Chimeric Autoantigen-T Cell Receptor (CATCR)-T Cell Therapies to Selectively Target Autoreactive B Cells
https://t.co/VeAgl3qz8J https://t.co/rN4ZLM5Ft8
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast available! Download where ever you get your podcasts and when can--rate, review and subscribe!
Rheum Manpower Needs - More Programs
https://t.co/xGXVFMkNra https://t.co/hcRGVMFZPE
Links:
Dr. John Cush RheumNow ( View Tweet)